Elekta (EKTA-B.ST) announced today that it will further develop its focus on cancer care providers and their patients through its acquisition of Kaiku Health. The Finnish company is best known for its app that monitors patient-reported outcomes, providing intelligent symptom tracking and management for healthcare providers in routine oncology care and studies.
The Kaiku Health app screens for patients’ symptoms, notifies the care team on their development and provides value-based personalized support for patients. It is easily implemented into existing hospital information systems and can be integrated with Elekta’s MOSAIQ® Oncology Information System (OIS). This makes Kaiku Health a valuable tool for healthcare teams to collate patient-recorded feedback and act immediately if anything unusual is reported.
Richard Hausmann, Elekta President and CEO, says: “Including intelligent patient-monitoring software in the Elekta portfolio supports the company’s oncology informatics strategy. This is a concrete step towards expanding our digital portfolio to further digitally connect our two most important stakeholders: our customers and their patients. Kaiku Health’s solution has demonstrated it can improve quality of life and reduce costs of healthcare.”
Lauri Sippola, Kaiku Health CEO and Co-Founder adds: “This is a very exciting step for Kaiku Health, but also for Elekta’s network of thousands of customers. Together we will continue to develop personalized digital interventions in order to help improve the lives of cancer patients globally. Measuring what matters to patients is paramount in value-based healthcare and it will benefit patients, healthcare providers and society.”
Joni Karsikas, Investment Manager at Tesi, comments: "Kaiku Health team has excelled in pioneering new approaches to patient-monitoring and its commercialization. With Elekta's vast network Kaiku's software can be used by more patients. In addition, positive acquisitions like this prove that there are interesting investment options among Finnish health tech companies."
Kaiku Health has modules for more than 25 types of cancer across different cancer care pathways. It is currently in use in over 40 European cancer clinics and hospitals. The acquisition took effect May 15, 2020 with Elekta owning 100 percent of Kaiku Health. Previous owners include, among others, Tesi and Debiopharm.
For further information, please contact:
Joni Karsikas, Investment Manager, Tesi
email@example.com, +358 40 827 0395
Lauri Sippola, CEO, Kaiku Health
firstname.lastname@example.org, +358 40 744 7481
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
Kaiku Health was founded in 2012 at Aalto University, Finland by five software developers deeply passionate about healthcare. Today Kaiku Health has grown into a company of 35+ in staff and the Kaiku Health platform is in clinical routine use in over 40 cancer clinics and hospitals all over Europe. With the help of its dedicated team, driven customers and leading life sciences partners Kaiku Health keeps on pursuing its vision: providing personalized digital health interventions for every cancer patient. Visit kaikuhealth.com or follow @KaikuHealth.
Tesi (Finnish Industry Investment Ltd) is a state-owned investment company that wants to raise Finland to the front ranks of renewing economic growth by investing in funds and directly in companies. We invest profitably and responsibly, hand-in-hand with co-investors, to create the world’s new success stories. Our investments under management total 1.3 billion euros. Ambition for ownership and success www.tesi.fi | www.dtg.tesi.fi | @TesiFII